Drug Utilisation Sub Committee (DUSC)

Page last updated: 24 November 2014

Drug Utilisation Sub Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee (PBAC) assesses estimates on projected usage and financial cost for medicines.

It also collects and analyses data on actual use (including in comparison with different countries), and provides advice to PBAC.

DUSC contact details can be found in PBS Contacts

The DUSC Outcome Statements provide a high level summary of the topics discussed at each DUSC meeting.  This includes summarised results and DUSC’s views on the utilisation analyses of PBS medicines and therapeutic areas (multiple medicines in a treatment area) considered at that meeting.  The Outcome Statement also provides notice of the PBS medicines and therapeutic areas selected for consideration at future DUSC meetings.

The DUSC Utilisation Analysis Public Release Documents provide public access to the DUSC utilisation analysis reports.  The DUSC considers the reports will assist stakeholders including consumers, health professionals, researchers and pharmaceutical sponsors, to better understand how PBS medicines are currently being used, the methods DUSC employs to analyse utilisation of PBS medicines and the PBS data available for these analyses.  The reports may also outline how the current utilisation of PBS medicines compares with the use as recommended by the PBAC.

The DUSC considers the publication of the DUSC Outcome Statements and Utilisation Analysis Public Release Documents provide greater transparency of the working of the DUSC and the utilisation of PBS medicines.  The DUSC considers that the publications uphold the National Medicines Policy, which states that consumers and health practitioners should be encouraged to understand the costs, benefits and risks of medicines.

Current Membership

Professor Geoff McColl is a rheumatologist and Professor of Medical Education and Training in the Melbourne Medical School at the University of Melbourne.

Associate Professor Sallie Pearson is a research academic specialising in clinician behaviour change, pharmacoepidemiology and pharmaceutical policy evaluation. She is the head of the Pharmacoepidemiology and Pharmaceutical Policy Research Group at the University of Sydney.

Ms Jan Donovan is a consumer advocate with experience on a number of committees in health, ageing and pharmaceutical policy.

Ms Debra Rowett is a clinical pharmacist and Director of the Drug and Therapeutics Information Service at the Repatriation General Hospital, South Australia.

Professor Libby Roughead is a pharmacoepidemiologist at the Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia.

Dr Rashmi Sharma is a general practitioner and Practice Principal of a large teaching practice in Canberra where she supervises nursing and medical students, interns and GP registrars. She is a Senior Lecturer at the ANU Medical School and President of the ACT Division of General Practice. She is a board member and medical educator for the regional general practice training provider, Coast City Country GP Training Ltd.

Dr Frances Wilson is Senior Staff Specialist in Psychiatry and Clinical Director, Adult Psychiatry Unit at Westmead Hospital. She is a Clinical Senior Lecturer at Sydney University.

Professor Emily Banks is a medically trained epidemiologist with interest and expertise in large scale cohort studies, pharmacoepidemiology, women’s health, and healthy ageing. Professor Banks is currently the Scientific Director of the NSW 45 and Up Study and an NHMRC Senior Research Fellow at the National Centre for Epidemiology and Population Health, at the Australian National University.

Associate Professor Anna Kemp is a research academic at the Centre for Health Services at The University of Western Australia specialising in the utilisation of publically subsidised prescription medicines in Australia and the impact of national health policy on their use.

Dr Suzanne Hill is a clinical pharmacologist previously employed as a Scientist in the Department of Medicines Policy and Standards at the World Health Organisation (WHO) in Geneva, Switzerland. Prior to this she was Associate Professor/ Senior Lecturer, Clinical Pharmacology, Faculty of Medicine and Health Sciences, University of Newcastle. She is the Chair of the PBAC.

Ms Elizabeth DeSomer is the nominated member from Medicines Australia.

Ms Belinda Wood is the nominated member from Generic Medicines Industry Association.

Dr Tracey Laba is a Research Fellow at The George Institute for Global Health specialising in health economics. Her main area of research interest is medications adherence.

Top of page